RxDoctor Payments DataLook up a doctor →

Anthony Spaedy, MD

Interventional Cardiology · Kansas City, KSNPI 1851384192

Payments from drug & device makers

$526,625in general payments, 2019–2025

Across 932 payments — averaging $565.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$195K
  • Boston Scientific$87K
  • Johnson & Johnson$79K
  • Medtronic$66K
  • Teleflex LLC$57K
  • Arrow International, Inc.$15K
  • plus $27K from 37 others
$12,425in research payments, 2019–2025

Across 6 payments — averaging $2070.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vascular Solutions, Inc.$12K

What the payments were for

  • Consulting fees$74,40019%
  • Speaking & faculty fees$241,77863%
  • Travel & lodging$37,91710%
  • Food & beverage$27,8057%
  • Education$2,5631%
  • Gifts$750%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$526,625 in reported general payments places this provider in the 95th percentile of 55 interventional cardiology providers in Kansas.

See all interventional cardiology providers in Kansas

Medicare billing

Part B allowed, 2024
$150,898
Medicare patients
636
Services billed
1,653

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban107$132,659
Repatha SureclickEvolocumab43$33,013
EntrestoSacubitril/Valsartan24$30,374
XareltoRivaroxaban26$28,584
JardianceEmpagliflozin11$6,528
Metoprolol Succinate185$2,687
Prasugrel Hcl18$1,887
Ezetimibe72$1,841
Rosuvastatin Calcium113$1,473
Clonidine13$1,009
Carvedilol71$876
Amlodipine Besylate137$817
Losartan Potassium99$720
Atorvastatin Calcium113$624
ClopidogrelClopidogrel Bisulfate68$579

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$11,509$132,659107 claims
NovartisEntresto$201$30,37424 claims
Johnson & JohnsonXarelto$79,171$28,58426 claims
Boehringer IngelheimJardiance$119$6,52811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 55 interventional cardiology providers in Kansas.

Other interventional cardiology in Kansas City

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →